liver

Macrophage-based therapies for liver cirrhosis are entering clinical trials, but key challenges remain before they become a viable treatment.

A novel immunotherapy targets the liver to promote tolerance to allergens in mice, promising durable allergy relief without the risk of severe reactions.

Sagimet’s denifanstat delivered significant improvements in disease activity and fibrosis for patients with metabolic dysfunction-associated steatohepatitis.

A liver enzyme affects fibrosis progression by altering metabolism of the sugar trehalose in the gut.

As an alternative to daily pills, a new RNAi drug could lower blood pressure with a twice-yearly injection.

With a high mortality rate and no treatment, alcoholic hepatitis is a tragic diagnosis. But a new molecule that alters patient epigenetics may become the first effective therapy for the disease.

Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.

Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.